OpenNashPodcasts

Leadership Next (Fortune)

Eli Lilly CEO On Why Making New Drugs Is Hard, Takes So Long, And Costs So Much

12 Nov 2024 · 34m · Dave Ricks, Diane Brady, Jason Garzadas · 25 quoted facts

▶ Play episodeOriginal source ↗

In brief

Eli Lilly CEO Dave Ricks argues that drug development is slow, risky and expensive because biology is still poorly understood, and that no amount of computing power removes that. Most Lilly scientists never work on a drug that reaches patients. Lilly's answer is speed, plus a focus on problems that cause the most human suffering at scale rather than where the market is today.

The main tension is between innovation and affordability. Ricks says medicines that are clearly valuable earn a premium and later become cheap generics. He also admits the US financing system leaves people exposed to high out-of-pocket drug costs and unequal coverage. He wants incremental, tested policy changes, not sudden swings, and sees obesity drugs funding a push into brain health.

Key insights

  1. Drug discovery takes 13-14 years, mostly failing

    Ricks says the industry needs 13 or 14 years from lab idea to approved drug. Most scientists never see a success in their whole careers, so Lilly tries to fail faster.

  2. Lilly says it halved development times

    Ricks says Lilly cannot predict which drugs will work, but it can run experiments faster. He says the company has cut its times roughly in half, so it learns about failures sooner than rivals.

  3. AI helps, but is not a magic button

    Ricks calls AlphaFold a real breakthrough that solves one discrete problem among hundreds or thousands of steps. He expects machine-aided discovery to be standard in about 10 years, but says humans must still do the last stretch of each step.

  4. US patients carry unusually heavy drug costs

    Ricks says Americans pay about 3% of hospital costs out of pocket but about 20% at the pharmacy. He says this is why drug prices draw so much anger, and he notes coverage is best for people with better jobs.

  5. Obesity profits may fund brain-health research

    Ricks says brain disorders such as Alzheimer's, Parkinson's, pain and mental health are where the most suffering lacks good answers. He suggests resources from the obesity drugs could be redirected to those areas.

Questions

Why does it take so long to develop a new drug?

Ricks says the industry needs 13 or 14 years to move from lab discovery through animal tests and three stages of human trials. Biology is still mostly a mystery, so ideas have to be tested carefully and many fail.

Will AI make finding new drugs fast and cheap?

Ricks is optimistic but says it is early innings. He says AI solves single steps, like AlphaFold's protein folding, while drug discovery has hundreds or thousands of steps, so he expects it to become the standard way in about ten years.

What is tirzepatide and how well does it work?

Ricks describes it as Lilly's weight-loss and diabetes drug that uses two gut hormones, not one. He says it helps people lose about 20% of body weight, versus at most about 5% from diet and exercise in Lilly's trials, and cut new diabetes diagnoses by 94%.

Why do people in the US pay so much for medicines?

Ricks says the US does not shield people from drug costs the way countries like Canada or those in Europe do. Americans pay about 20% of pharmacy costs out of pocket, versus about 3% of hospital costs, and he says coverage is worst for people on Medicaid.

Should people who are not overweight take these weight-loss drugs?

Ricks says no. He says there is no data showing the drugs are safe or effective for people who are not overweight, and extra demand could limit supply for patients who need them.

Facts

Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.

Dave Ricks says drug development across the pharmaceutical industry takes 13 or 14 years in total, and most Eli Lilly scientists never work on a successful drug in their careers.

“In total, in the industry, that takes 13 or 14 years. Most of our scientists, the thousands of people who work here, actually never work on something that's successful in their whole career.”

0:03:19 · Dave Ricks · Drug development

Dave Ricks says Eli Lilly has cut its drug development times roughly in half and fails faster than other companies.

“we've cut our times in roughly half. So we're failing a lot faster than others.”

0:04:37 · Dave Ricks · Development speed

Dave Ricks says he spends roughly 25 to 30 percent of his time working with Eli Lilly's scientific team.

“I probably spend, I don't know, 25, 30 % of my time working with the scientific team”

0:03:41 · Dave Ricks · CEO role

Dave Ricks says Alphabet led a major breakthrough on protein folding with AlphaFold.

“there was a big breakthrough on protein folding that Alphabet led in AlphaFold.”

0:05:38 · Dave Ricks · AlphaFold

Dave Ricks predicts machine-aided drug discovery and development will be the standard approach in about ten years.

“machine-aided drug development and drug discovery, I think, in 10 years would be the way.”

0:06:13 · Dave Ricks · AI in drug discovery

Dave Ricks says Americans on average pay about 3 percent of hospital costs out of pocket but about 20 percent of pharmacy costs.

“So if you go to the hospital, we pay 3 % of that cost out-of-pocket in the US on average. If we go to the pharmacy, we pay 20 % out-of-pocket.”

0:10:44 · Dave Ricks · Out-of-pocket costs

Dave Ricks says Eli Lilly invented Prozac, which is now a cheap generic standard of care for depression worldwide.

“we invented Prozac, which is a standard of care to treat depression globally. It's almost free.”

0:11:41 · Dave Ricks · Prozac

Dave Ricks says the first incretin hormone, GLP-1, was made into a drug in 2005.

“The first one we identified and made a drug out of was GLP-1. Actually, we did that in 2005.”

0:14:22 · Dave Ricks · GLP-1 drugs · 2005

Dave Ricks says Novo Nordisk ran the studies that revealed the weight-loss effect of weekly GLP-1 drugs, and Eli Lilly followed with its GLP-1 drug Trulicity.

“Novo Nordisk actually did those studies and we followed, we had a drug called Trulicity, still do.”

0:14:50 · Dave Ricks · GLP-1 drugs

Dave Ricks says tirzepatide is a dual-acting drug that uses two gut hormones, GLP-1 and GIP.

“Tirzepatide is a dual acting. So it uses two hormones.”

0:14:50 · Dave Ricks · Tirzepatide

Dave Ricks says about a billion people worldwide, including 100 million Americans, are overweight or have obesity.

“a billion people on planet earth have obesity overweight that's a lot 100 million americans”

0:15:31 · Dave Ricks · Obesity prevalence

Dave Ricks estimates that about 40 percent of US healthcare spending is tied to obesity.

“Maybe 40 % of US healthcare spending is tied to obesity.”

0:15:31 · Dave Ricks · Obesity costs

Dave Ricks says tirzepatide reduces body weight by about 20 percent on average.

“And so it's really helping reduce weight on average 20 % of body weight.”

0:16:00 · Dave Ricks · Tirzepatide

Dave Ricks says a Lilly study showed tirzepatide reduced new diabetes diagnoses by 94 percent.

“now we're demonstrating it also affects the downstream diseases, like we just showed, it reduced new diabetes diagnosis by 94%.”

0:16:00 · Dave Ricks · Tirzepatide

Dave Ricks says that in Lilly's clinical trials, people on strict diet and exercise regimens lost at most about 5 percent of body weight after a year.

“we put people on strict diets and exercise. and after about a year, they lose about 5 % at most of their body weight.”

0:17:12 · Dave Ricks · Diet and exercise

Dave Ricks says US taxpayers do not currently pay for obesity drugs because the government does not reimburse them, though about half of commercial payers do.

“In the U.S., it's important to note that taxpayers are bearing none of the cost. The U.S. doesn't reimburse these.”

0:16:42 · Dave Ricks · Obesity drug coverage

Dave Ricks says Eli Lilly originated the $35 out-of-pocket cap on insulin, starting it in 2019 in the employer market.

“Actually, Lilly invented that. We started doing that in 2019 for the markets where we could, which is the employer market.”

0:22:00 · Dave Ricks · Insulin cap · 2019

Dave Ricks says Lilly proposed the insulin out-of-pocket cap to the prior US administration as a Medicare experiment, and the current administration later made it law.

“We then took that to the prior administration and said, why don't we try this as an experiment in Medicare?”

0:22:00 · Dave Ricks · Insulin cap

Dave Ricks says he spent time running Eli Lilly's Canadian business and lived in Canada.

“I spent some time running our Canadian business and lived there.”

0:21:00 · Dave Ricks · Career

Dave Ricks says many telehealth visits allowed during the pandemic were later cut, which he regards as a loss of efficiency.

“we allowed for a lot of telehealth visits during the pandemic Those then got cut.”

0:24:26 · Dave Ricks · Telehealth

Dave Ricks cites Eli Lilly's latest Alzheimer's drug as an example of progress against neurodegenerative disease.

“Our latest Alzheimer's drug, Kassanla, is an example of that.”

0:29:41 · Dave Ricks · Alzheimer's

Dave Ricks says Lilly and others might have good non-opioid pain drugs in five to seven years.

“that maybe in five to seven years, we could have good pain drugs that can alleviate the need for opioids.”

0:30:48 · Dave Ricks · Pain drugs

Dave Ricks says Eli Lilly led a wave of mental-health innovation with Prozac and Zyprexa, but there has been little since.

“Mental health, there was a big wave of innovation Lilly led with drugs like Prozac or Zyprexa for bipolar and schizophrenia.”

0:30:48 · Dave Ricks · Mental health

Dave Ricks says the biggest change behind rising obesity over 40 years is processed foods, more than exercise or quantity of food.

“That's a little bit true, but the biggest thing that's changed is processed foods.”

0:26:32 · Dave Ricks · Obesity causes

Dave Ricks says Eli Lilly has now caught up with supply of its obesity drug, but only just.

“we have a situation where we're now caught up with supply, but just”

0:18:01 · Dave Ricks · Drug supply

Chapters

  1. 0:03:19Why a 13-14 year drug pipeline mostly ends in failure

    Ricks explains how Lilly invents new drug candidates and why most scientists never see one succeed. This sets up why development is so slow and expensive.

    “In total, in the industry, that takes 13 or 14 years.”
  2. 0:04:37Speed as Lilly's edge, and where to look

    Ricks says Lilly cannot predict winners, so it speeds up experiments and aims at big health problems, not today's markets.

    “we've cut our times in roughly half. So we're failing a lot faster than others.”
  3. 0:06:13AI's promise and its limits in drug discovery

    Ricks is optimistic about AI but warns that tech-industry speeches underestimate how many separate problems must be solved.

    “it's not like you can write some code, turn on a computer and make a new drug.”
  4. 0:07:56Leading a cross-disciplinary, trust-dependent industry

    Ricks says pharma leaders must tie together many technical fields while keeping the trust of doctors and patients.

    “we really have to thread together almost like a cable made of strong individual parts”
  5. 0:10:44Who pays for medicines in the US versus abroad

    Ricks contrasts systems that shield patients from cost with the US, where patients bear much more of the drug bill.

    “If we go to the pharmacy, we pay 20 % out-of-pocket.”
  6. 0:16:00Tirzepatide and the obesity opportunity

    Ricks explains the incretin drug class, tirzepatide's results, and why Lilly sees obesity as a disease of huge scale.

    “it reduced new diabetes diagnosis by 94%.”
  7. 0:22:00Fixing health policy incrementally, with insulin as the example

    Ricks argues for less politics and more tested experiments, citing the $35 insulin cap that began as a Lilly program.

    “Lilly invented that. We started doing that in 2019 for the markets where we could”
  8. 0:29:16The next frontier: brain health, pain and mental health

    Ricks names neurodegeneration, pain and mental illness as the next big targets and says obesity profits could help fund them.

    “without a lot of good answers from medicine, brain health is probably the biggest category.”

Transcript

0:00:04
Diane Brady

Leadership Next is powered by the folks at Deloitte, who, like me, are exploring the changing rules of business leadership and how CEOs are navigating this change. Welcome to Leadership Next, the podcast about the changing rules of business leadership. I'm Diane Brady. from transformative weight loss treatments to a potential blockbuster for Alzheimer's. Dave Ricks of Eli Lilly is having a banner year. All that innovation, of course, is expensive, as we know, because drug company CEOs are often pilloried in the court of public opinion.

0:00:44

But take a listen as I talk to Dave about the innovation process, how they're using AI, and most importantly, the developments he sees that could truly transform human health. Dave, to start first, thanks for joining us. You're the world's largest pharmaceutical by market cap. Was that ever a goal or is that, I'm never quite sure how to read market cap as a measure of success.

0:01:13
Dave Ricks

Well, thanks for having me on, Diane. Great to be here. Of course, we're really proud of the success of the company, but I think of that as more like an outcome that is derived from focusing on the things that create the value, not a goal by itself. I think we have other goals, like how many new medicines we want to introduce per year and how big a difference we're going to make in conditions like Alzheimer's and obesity.

0:01:38

But if those lead to investors thinking we're creating more value, that's great. But that's not the end.

0:01:45
Diane Brady

Of course, of course. And, you know, one of the things I grew up in a time when you'd think of big pharma and it would be judged by the pipeline, the late stage pipeline, the early stage pipeline. Obviously, that's that's critical. You've had a terrific pipeline. pipeline. But tell me, if you're to step back 30 ,000 foot a second, how would you like us to think about drug companies and how they're run? Because it seems like a very simplistic way to just look at the lineup and then sort of do a check or not.

0:02:19

Our industry is really, to me,

0:02:21
Dave Ricks

very complicated, but very interesting. And it's so complicated. Often we reduce it to little soundbites. We talk about like a portfolio as if we're buying and selling assets, but we create the assets. So it all starts in laboratories and we have many thousand PhDs at a company and they come to work and put on lab coats and they try to find basically new matter. So we invent new chemical entities or biologic entities that interfere with a disease process.

0:02:51

And they have to do that first in like a piece of glass, and then they do it in an animal model. And then when it's safe enough, and we've proven usually after four or five years that that idea is good enough to try in people. We try it in early stage studies, and then we do mid-stage studies and then late-stage studies, all to show that this new matter, this substance, a chemical or a biologic can actually change a disease in a safe and effective way for someone.

0:03:19

In total, in the industry, that takes 13 or 14 years. Most of our scientists, the thousands of people who work here, actually never work on something that's successful in their whole career.

0:03:29
Diane Brady

How do you make the judgments then? Because you're making these massive bets, to your point, some of which you don't know if they're going to pay off for a decade plus.

0:03:41
Dave Ricks

Actually, I'm pretty involved in that. I probably spend, I don't know, 25, 30 % of my time working with the scientific team to point that capability in the right direction. And maybe a few things we do differently at Lilly. So one of the things I've focused on extensively in my tenure is speed. So you mentioned failing fast. We're not engineering a product, right? We can't make anything. Like I'm on the board of a software company and they can manipulate digits and probably do almost anything you could imagine.

0:04:08

It's really the imagination that's the barrier. Here we're dealing with biology, which is still mostly a mystery. I mean, we know a lot about how biology works in the human body, but not nearly as much as we want. So we have to try things that we think will work and prove they do in a controlled way. But we can affect the speed at which we run those experiments. And that's been something that's been a hallmark of Lilly's success is speeding up both preclinical work and in-clinic development.

0:04:37

I mentioned that 13, 14 years. We can't so much maybe predict what will work and what won't, but we can go faster. And we've cut our times in roughly half. So we're failing a lot faster than others. And that's an advantage. The other thing we can control is where we look. So I'm pretty involved in this. Where should we direct the scientists to examine? And here we focus on big human health problems, because I think that's what Lilly is for, doing things at scale, but also focusing on where the most suffering is in a way.

0:05:09

not where the market is today. Because if you focus where people are making success today, well, that'll be gone in 13 or 14 years. We need to go just where the basic human health problems

0:05:21
Diane Brady

are. Let me go back to that speed question, because I would imagine AI could have a transformative impact. I'm already hearing about companies when they talk about the speed coming up with the right molecules, testing, et cetera. What impact do you think AI is going to have on drug discovery?

0:05:38
Dave Ricks

I think significant. I'm pretty optimistic on that. That said, I think we're in very early innings. People give speeches on this topic from the tech industry, and sometimes I worry that they don't understand the complexity of what we're talking about. I mean, there was a big breakthrough on protein folding that Alphabet led in AlphaFold. And it's really interesting. And it solves a pretty discrete problem really pretty well, not perfectly, not good enough actually for drugging the target, but for helping us decide which targets can be drugged, et cetera.

0:06:13

But that is one of hundreds, maybe thousands of steps that need to get solved. And even that one, it needs a human to do the last 10 yards, if you would, to make it useful for drug discovery. So we'll knock down these walls one by one and machine-aided drug development and drug discovery, I think, in 10 years would be the way. And it will be faster and better. But it's not like you can write some code, turn on a computer and make a new drug.

0:06:40
Diane Brady

I want to, before we get into some of the specifics of the drugs, which I know are fascinating to people, this is a podcast about leadership. And I often think we treat leadership like it's some, you know, generic concept that can transfer from industry to industry. But there are sort of unique idiosyncrasies, especially you're in an industry, of course, where you've got big customers, you're managing scientists, you know, very creative people doing work in the lab.

0:07:09

what do you think are some of the hallmarks to be a successful leader in the pharmaceutical sector?

0:07:16
Dave Ricks

I suspect every sector has some idiosyncrasies that really matter. I also think there are some general things that really matter. So it's probably overlapping those two ideas that leads to highly successful leaders. In medicine, I think there's two or three things that stand out to me. One is the highly cross-functional technical nature of what we do. So I think in other industries, there maybe aren't so many different technical disciplines that need to thread together. We just talked about AI and we have many, many people here, experts in that, who don't know anything about a human liver cell, let's say.

0:07:56

And we have experts who know a lot about that, but don't know anything about AI. And then we have experts that know how to make organic chemicals that are safe to metabolize and humans who don't know anything about those other two topics and on and on and on. So we really have to thread together almost like a cable made of strong individual parts to make an even stronger united thing, all these technical disciplines at scale. Appreciating that and paying attention to that, I think, is maybe a little bit unique in our space.

0:08:26

And then on the other side, it's a hugely technical industry. It's also a hugely important human industry. And so we can't lose through that why we're doing what we're doing, which is somebody today is being told you have a terrible neurogenic condition or you have obesity and you really should do something about it. And I think we often have lost our way as an industry or even as a company when we don't pay enough attention to that, which is how we show up in those markets, how we think about introducing our medicines, about integrity, about truthfulness, et cetera, is incredibly important.

0:09:06

And really preserving the trust we have with healthcare practitioners and patients is critical. Those two skills in our sector have not always flown together. And when they don't, I think you can get into a lot of trouble.

0:09:18
Diane Brady

Where are we in the conversation around drug costs, Dave? I mean, even the fact that you're a global company, and of course, the U.S. is such a different market from other parts of the world, but that's something that comes up as a political issue, as a personal issue. And there's this tendency to look to the drug companies, even though you're just one player in a broader ecosystem. But how do you think we should be feeling about it right now?

0:09:44
Dave Ricks

Yeah, well, that's an example of the second thing I spoke about, which is like, Personally, I think we should make products that we can charge a premium for because they're so valuable, that they create value for the healthcare system and for people as individuals. We have, though, a strange way to finance medicines, particularly in the U.S. Outside the U.S., they have also strange ways. You have two very different situations. So outside the U.S., the discussion is all about affordability to the system.

0:10:13

And almost every developed country has decided we are going to largely shield individuals from any responsibility financially for medicines. So it becomes the burden shifts to the taxpayer, essentially, or the insured, whoever's paying the insurance. And we have a lot of discussion and debate about whether a new medicine is worth it, meaning is it producing enough excess benefit in the health system to justify its use? On the other hand, in the US, we have hardly any discussions about that question.

0:10:44

We have decided to not shield people from the cost of their medicines in the same way that, for instance, Europe or Canada have. People have enormous out-of-pocket responsibility, not just for medicine, but actually disproportionately for medicine. So if you go to the hospital, we pay 3 % of that cost out-of-pocket in the US on average. If we go to the pharmacy, we pay 20 % out-of-pocket. So people are much more exposed to the cost of medicines, even if they're hugely valuable.

0:11:12

So we have to play in both those worlds and be very sensitive to that. Again, if we create inventions that are so useful that it's obviously helpful for the system and obvious that people are benefiting directly, this conversation, the temperature drops. When we create medicines that are not so obviously useful, it's a tougher one. But we always have to be sensitive to this. and then recognizing in the long term, medicines go generic and become very cheap commodities.

0:11:41

We never really take enough credit for that, but we should. I mean, we invented Prozac, which is a standard of care to treat depression globally. It's almost free. It's really cheap to use because it's generic. And that's something we did. That's part of the value equation as well.

0:11:59
Diane Brady

Generative AI has been a transformative force in the business landscape for the last 18 months. According to the latest Fortune Deloitte CEO survey, more than half of CEOs are experimenting with generative AI in their own daily activities and, of course, trying to spread it throughout their organizations. I'm joined by Jason Garzadas, the CEO of Deloitte US, which is the longtime sponsor of this podcast. Jason, good to see you. Hi, Diane. It's great to be with you.

0:12:26

How are businesses integrating AI into their organizations? Where do you see the most substantial benefits?

0:12:34
Jason Garzadas

I think it's true, as you say, that every organization wants to capitalize on the benefits of AI, particularly generative AI. The benefits have been largely around efficiencies to date and looking for ways to automate routine tasks and create cost savings wherever possible.

0:12:49
Diane Brady

When you think about how much change there's been the last 18 months, really curious, how do you think it's going to evolve in the next 18 months, 36 months?

0:12:58
Jason Garzadas

I think we're actually needing to change our timing horizon. By all indications, we're more in six-month intervals. And I think that's exciting, but also a challenge. Enterprises aren't accustomed to working in that type of cadence and with that type of pace. And so the winners, if you will, will be those that can assimilate this technology that quickly, either with vendor partners that they already do business with or in their own internal development and use case development, which I think is putting real strain on organizations' ability to adapt that quickly.

0:13:29

This is a perfect instance where leadership has to be in sync to assimilate technology that quickly. I think as a CEO, it's important that we lead by example. So I've been through all the training. I've been through all the productivity tools that we have available within our organization. But then more broadly, we've embarked upon a significant investment to deploy this across all we do.

0:13:48
Diane Brady

I'm feeling the urgency, Jason. Thanks for joining us.

0:13:52
Jason Garzadas

Thank you, Diane.

0:13:56
Diane Brady

Yeah. Let's go to what the hottest drug is right now, least among, certainly from the headlines, which is those GLP-1, you know, I think, is it Tirzepatide, am I pronouncing it correctly? The weight loss drugs. I mean, first of all, we see it as, it's a category versus a drug, right? Talk about the impact that that has had.

0:14:22
Dave Ricks

Well, obviously a huge impact, but just to go back on the category. So the category we would call is so-called incretins. These are hormones produced by our gut when we eat. The first one we identified and made a drug out of was GLP-1. Actually, we did that in 2005. So that's a long time ago. You may say, well, geez, it seems like a much more recent conversation. That's true. We use them for diabetes, but until we had weekly acting ones that we learned to titrate up, we didn't see the weight effect.

0:14:50

Novo Nordisk actually did those studies and we followed, we had a drug called Trulicity, still do. That's a GLP-1. Tirzepatide is a dual acting. So it uses two hormones. That's why it's a little better actually at helping people lose weight and controlling diabetes than only GLP-1s. And because of that, I think we see really breakthrough results in a lot of people, both in diabetes, but also now in obesity management or chronic weight management. this is a when i when i spoke about problems we want to work on we want to work on problems that are scaled problems for mankind and make drugs that are super useful and here Tirzepatide is a great example of that it's a scaled

0:15:31

problem a billion people on planet earth have obesity overweight that's a lot 100 million americans and it's a condition that causes other diseases 230 recognized diseases stem from overweight or obesity in adults. So if we can arrest obesity, we can have a big impact on human health. Maybe 40 % of US healthcare spending is tied to obesity. So this is a big problem. That's what Lilly's for. And Tirzepatide is super effective. And it's our third iteration in the class.

0:16:00

We had the first GLP-1, which was daily, then a weekly, and now we have GLP-1 GIP. And so it's really helping reduce weight on average 20 % of body weight. And And now we're demonstrating it also affects the downstream diseases, like we just showed, it reduced new diabetes diagnosis by 94%. So hugely important medicine.

0:16:20
Diane Brady

You know, there is conversation as well around some of the moral hazard, if that's the right way to put it, that these are drugs that people may have to stay on for life, that they are drugs to address what really fundamentally may be lifestyle issues for some people. How do you respond to that, especially in those markets where taxpayers are bearing the brunt of the cost?

0:16:42
Dave Ricks

In the U.S., it's important to note that taxpayers are bearing none of the cost. The U.S. doesn't reimburse these. And actually, few countries do so far for a condition which is identified by experts as a disease, but not recognized as such by payers in every case. In the U.S., also about half of commercial payers, so people, employers, pay for these because they are recognizing it's a disease. That's an important discussion we can come back to, stigmatizing people with obesity and treating it not like a disease when the science says it is.

0:17:12

So that's my first response is you don't have to listen to Lilly about this. You can just read what experts say is once you develop overweight or obesity, it is pathologic. It's difficult to, very difficult to use traditional tools like diet and exercise to lose weight. We see this in our own clinical trials where we put people on strict diets and exercise. and after about a year, they lose about 5 % at most of their body weight.

0:17:37

That's what dieting does. And by the way, they have trouble staying in the regimen. People don't like it. They don't feel good. Whereas on the drugs, people lose 20 % or more of their weight, on Tirzepatide specifically. So the drugs work and they add to the diet and exercise regime for people who are already overweight. But that's different from people who don't want to become overweight or people who aren't overweight and want to lose weight. And here we recommend not using these drugs.

0:18:01

We don't have data, number one, so it's not proven to be safe or effective. Number two, we have a situation where we're now caught up with supply, but just. So if we have too many people who aren't obese or overweight using the drugs, we won't be able to help those that are and really need the drugs.

0:18:19
Diane Brady

Do you ever think about this concept of almost a healthcare apartheid comes to mind? But, you know, you're talking about some very real issues where when you think about obesity, it's also something that's quite linked to poverty and that, you know, really the reality is a lot of people can't afford drugs when the cost is borne solely by them.

0:18:40
Dave Ricks

Yeah, I'm really concerned about that issue. We're concerned about that in every disease. And I think one of the things that there's no perfect health care system. One of the things that in our country, in the US, we do a poor job of is managing what we call health equity. Other countries make that trade-off pretty well. They shield people, as I mentioned earlier, from most of the cost if they get sick with a disease. Here, I'm including obesity as a disease that people should be shielded from, and these systems aren't doing that.

0:19:09

But mostly they do that. I think that's an area for improvement in the US. We do see big differences in reimbursement levels, and it is mostly a regressive system. that the better job you have, the better healthcare you get. And that seems wrong on many levels. And we'd like to see that changed. Yeah. And medicines in particular, you see more differences in that. So the better medical coverage for pharmaceuticals is really skewed toward better jobs. Medicaid for people who have not a good job or not a job at all has some of the worst coverage.

0:19:46

So that's something that should change. We feel strongly about that. We speak out about that. And we're willing to sit down and negotiate to help make that happen. And we do do that routinely. But it's not a pharmaceutical job to make everything affordable. That's the healthcare system's job. That's important. That's why we have healthcare. We pay in in advance of getting sick so that when we do get sick, we're shielded from the cost. I think our system doesn't work as well in that manner.

0:20:12
Diane Brady

Is there anything you would do if I were to put whichever hat, policy hat you pick, what would you do to change things? I mean, obviously, we're talking about a very complex set of variables here, and systems that are in place and hard to dislodge. But is there anything in the immediate term that you think would help to address an issue that tends to make people kind of feel sad and

0:20:37
Dave Ricks

look at their feet, which is the word healthcare? Yeah, well, that's a big question, Diane. I mean, first of all, I think we have to be careful. And sometimes, you know, we're in election season, and people say things that sound good, but are very difficult to do. So first of all, I think it'd be good if we had less politics in the healthcare discussion and we agreed on the goals of what the system should be. One thing we do well in the U.S.

0:21:00

is if you have good insurance, it's easy to get innovation, right? And so, you know, I spent some time running our Canadian business and lived there. And I knew lots of people when they got a serious condition would just drive to the U.S. because in that country, it was difficult to get whether a new medicine or a new procedure. If you had cancer, you'd go to the Mayo Clinic in Minnesota. You wouldn't go to the Quebec hospital where you were living.

0:21:23

So we don't want that, right? We like that part of our system. On the other hand, as you just mentioned, for common conditions for people who don't have good jobs or a job at all, we don't do a very good job. If we just try to fix one of those problems like a whack-a -mole, we might have a tertiary problem emerge. So we have to be careful and move more incrementally through time. I'd like to see more of a group of people who are focused over the long term on making subtle improvements over time and embracing experiments that naturally occur in the health system and letting those become the policy after they've proven to work.

0:22:00

One example of this, by the way, that is in the election cycle is this idea of $35 cap on out-of-pocket expenses for insulin. So what's the history here? Actually, Lilly invented that. We started doing that in 2019 for the markets where we could, which is the employer market. We then took that to the prior administration and said, why don't we try this as an experiment in Medicare? And they did it and it worked. And then now this administration has embraced that as the law.

0:22:28

I think that's the kind of policymaking we should have, but on hundreds of issues so that we can evolve the system towards something that's more just and doesn't give up innovation. I think we

0:22:40
Diane Brady

kind of wildly jerk back and forth. Right? I mean, not in a bad, you're not a charity. You do need,

0:22:45
Dave Ricks

you've got shareholders. No, no. There won't be innovation if people don't have an incentive to invest at risk, right? That's embracing that capitalist idea, I think is highly consistent with better healthcare. But I think a system that promises easy solutions, probably too good to be

0:23:01
Diane Brady

true. Let me just follow up with one quick thing I think about, which is the demographic trends in this country and others is really skewing older. And many of those people going into the category, frankly, of Medicare, which to your point, doesn't compensate you for drugs to the same extent that private employers do. As the country becomes older on average, how do you think about that in terms of your customer base and also the revenue shifts?

0:23:29

Well, that's a global issue,

0:23:31
Dave Ricks

actually. So I think if we look at developed markets everywhere, actually, the US is moving its demography slower than Europe or Japan, for instance, or China. So these huge countries with a lot of economic power are actually faced with a much more... So I think we're going to learn from them. That's the first thing I'll say. The second thing is we need to make healthcare delivery in the federal system more efficient. I think that's hard. I think governments struggle with that.

0:23:57

There's a lot of calcification of old rules that get in the way of efficiency. And one of the benefits of a market-driven healthcare system, which there's a lot of critique of that, is that it is more responsive and dynamic. And I think we could use a little more of that in the federal program. So it could evolve towards something more efficient and effective. More experiments would be a way to do that from the center. And one of the ways to think about efficiency would be to use more technology, biotechnology, but also information technology.

0:24:26

I think one little example is we allowed for a lot of telehealth visits during the pandemic Those then got cut. One of the first things, even though that's probably a lot more efficient way to see a doctor. So I think we just need to embrace innovation.

0:24:40
Diane Brady

Let me turn to the personal. What do you do yourself to stay healthy?

0:24:46
Dave Ricks

Well, I work hard at it.

0:24:48
Diane Brady

I mean, on a macro level.

0:24:50
Dave Ricks

Yeah. Fortunately, I have enjoyed good health. And I worry about, you know, I have aging. My mother passed a few years ago. My father's in a nursing home and has illnesses, chronic illnesses. And I'm 57. Like a lot of people in my age bracket, you begin to realize, whoa, that's not too distant for me. So let me work hard at this. I've always been physically active. I think when I turned 50, I started to learn I can't produce enough calorie output to manage this if I don't manage my food input.

0:25:19

And increasingly, I'm focused on what I eat, not just how much I eat. And I think there's a lot of literature and science I read about that. My wife's a physician and she really likes this topic. So it helps me make better choices on that. And then mental health, super important. What do you do to get away from it? I'm in a job that probably looks stressful from the outside. And I think there's a lot of stressful jobs in the world, not just the CEO ones, but you have to manage stress and anxiety and with relationships and faith.

0:25:49

And here I think activity and movement helps me do that too. Alone time, having hobbies and other things. So I do all those things like probably many other people, but being disciplined about it is the most important thing.

0:26:02
Diane Brady

So Dave, what have you removed from your diet?

0:26:05
Dave Ricks

Yeah, yeah. I'm focused currently on removing basically processed foods. There's a lot of literature on the obesity crisis, by the way, and a lot of theories about why 40 years ago we had obesity was a pretty rare condition and now it's so common. One of them is we exercise less, but actually that's not totally true. movement in our society dropped maybe 80 years ago when we had cars and mass transportation, but it's been pretty stable actually since.

0:26:32

Another one is that the quantity of food that we eat has changed. That's a little bit true, but the biggest thing that's changed is processed foods. So for all kinds of reasons, I'm trying to avoid putting ultra processed and processed foods in my body. So eating more vegetables and fruits and meats that haven't been through a

0:26:52
Diane Brady

things you recognize to be food it's very good advice for everyone exactly yeah yeah it's interesting you mentioned alone time and i'm not this is not a therapy session here but i'm always intrigued a lot of ceos i meet are actually introverts you know and that by that i mean taking energy from being having that alone time versus energy from the crowd i know it's hard to classify yourself necessarily as one or the other but do you think of that in terms of how you

0:27:21
Dave Ricks

energize and refresh? Yeah, all the time. I think maintaining energy for CEOs is a really important topic because when you walk in the door, imagine the building, you're on and you're not really off until you're in your private space, which could be 14 hours later. For some people that's energizing, I think probably most CEOs over-represent how energizing that is and under-represent how much they have to charge their batteries to get ready for that. Whether it be in a media interview like this or just going to the cafeteria.

0:27:53

People make judgments about how the company's doing as employees or investors every time they look at you. So that's a responsibility we have. I'm like on Myers-Briggs. I'm like right on the line of an E or an I. So I'm right in the middle. And for me, I need a little bit of both. I enjoy being around people who I've known before I was here because I feel like I can relax a little bit and there's less of a kind of that on stage thing.

0:28:22

And I like social engagement, of course, with family, but my kids are all out of the house now. So there's less of that. And at the same time, I do need some time like in my little bubble. Often that's when I'm working out or sometimes going for a walk with my dogs or, you know, for fun. I like to get really away. Like I go to the woods and like hike through mountains and stuff or ski in the backcountry.

0:28:45

And those moments give me sort of solitude. That's good too. So like at work, it has to be a balance. Yeah. Let's look around the corner a bit to end,

0:28:55
Diane Brady

because I know I'm fascinated with some of the things you've said about the next decade really being the decade of the brain, so to speak, and the work that you're doing in that area. Such a huge issue, such a fear factor for so many people. And by brain, I mean, not just Alzheimer's, but you mentioned mental health. What excites you there?

0:29:16
Dave Ricks

Yeah. Well, first of all, if we look at back to our mission, which is to arrest human suffering, and if we do that well, we create a lot of value, and that creates value for the healthcare system, for individuals and the company. If we look at where the suffering is at scale around the world, without a lot of good answers from medicine, brain health is probably the biggest category. Cancer is a big problem. Cardiovascular health is a big problem.

0:29:41

But here I see a little less history, recent history of success. But I'm optimistic on the future, starting with neurodegenerative conditions, which sound terrible, and they are. But actually, scientifically, we're starting to unwind the threads of what causes them. Therefore, we can drug those targets. We can make medicines that can arrest it. Our latest Alzheimer's drug, Kassanla, is an example of that. But I think we can replicate some of the success of that program in things like Parkinson's, ALS, other terrible conditions, which nobody wants and are a big societal problem.

0:30:15

That's wave one, maybe. I think another area that is important is pain. So here in the U.S., we've had a terrible history with use of pain medicines, which are probably worse than the condition to begin with as drugs. They're old. Opioids are built on really natural medicines that are centuries, if not more millennium old, and we need to stop using them at scale and for chronic pain. And we've seen the terrible consequences of that. We need innovation there.

0:30:48

Pain is still the number one reason people go to the doctor around the world. So we're working on that problem. And I think there are some things in our pipeline and others that are getting me excited that maybe in five to seven years, we could have good pain drugs that can alleviate the need for opioids. Mental health, there was a big wave of innovation Lilly led with drugs like Prozac or Zyprexa for bipolar and schizophrenia. But we haven't really had innovation beyond that cycle.

0:31:13

I think we're just looking over the horizon here and we can see maybe some new ideas. Those might be more like a decade away, but boy, what would be more important than that? I think, especially in young people today, I'm really concerned about mental health in developed and developing world, and we can make a difference there. So I'm a techno optimist as it relates to pharmaceuticals and medicine. And I think when we train our scientists, we move that engine, point them at problems, they're pretty good at solving them.

0:31:43

They need time and money and expertise, but here we could potentially use some of the huge resources we're generating from the obesity problem, which we're solving and train them on brain health, what a good outcome that would be for the world and for

0:31:57
Diane Brady

Lilly. Well, and investors would say, of course, there are none better. One final question I've always wanted to ask Big Pharma, because I talk to so many people in Silicon Valley where longevity is about living longer, maybe even living forever. Let's hope not. How do you think about that? Just any advice to us when we start to look at longevity and it's the longevity economy, me. How does the CEO of Eli Lilly want us to think about longevity?

0:32:24

Mostly living better. I think

0:32:26
Dave Ricks

the idea that we're prolonging life is true, sort of condition by condition. We come at it sort of an atomic level like that, which is where's the suffering solve the suffering. And as a consequence of that, people may live longer. I mean, take obesity. We know there's a difference in life expectancy if you're obese versus you're not. So if we can have people lose weight, reduce their exposure to long-term illness like heart attacks and diabetes, great.

0:32:52

But we're not starting by saying, let's just have people live longer per se. That's not what we do. We may get to the same place. And anyway, I think the world is leveling up health and leveling up food in a meaningful way in our lifetimes. And so life expectancy globally will climb. The demography is real. So if we're going to live longer, we might as well live better while we're living longer. And I think that's about avoiding disease and having a full life and rich life and hopefully enjoying that time we're here on the planet and making a difference for others.

0:33:26

That's how I think about it. And our role is to solve the disease problem, which, you know, that's the worst day you're having is when you get told you have a new disease and we want to solve it when you have it and maybe prevent it if we

0:33:38
Diane Brady

can. That's what Lilly's for. Well said. Thanks so much for joining us, Dave. I've enjoyed the conversation. Thanks, Diane, for having me. Leadership Next is edited by Nicole Vergala. Our audio engineer is Natasha Ortiz. Our producer is Mason Cohn. And our executive producer is Hallie Steiner. Our theme is by Jason Snell. Leadership Next is a production of Fortune Media. Leadership Next episodes are produced by Fortune's editorial team. The views and opinions expressed by podcast speakers and guests are solely their own and do not reflect the opinions of Deloitte or its personnel, nor does Deloitte advocate or endorse any individuals or entities featured on the episodes.